Viewing data from:

RIVASTIGMINE

ANDA

RIVASTIGMINE | A209063 | BRECKENRIDGE PHARMACEUTICAL INC

3 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: EXELON(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 3 NDCs

Highest NADAC/Unit

$1.85

per ea

Lowest NADAC/Unit

$1.73

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
51991089930RIVASTIGMINE 13.3 MG/24HR PTCH	$1.85	EA	Generic	—	2026-06-17
51991089730RIVASTIGMINE 4.6 MG/24HR PATCH	$1.81	EA	Generic	—	2026-06-17
51991089830RIVASTIGMINE 9.5 MG/24HR PATCH	$1.73	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain16 active DMFs2 inactive

14 active API suppliers hold Drug Master Files for this ingredient.

DR REDDYS LABORATORIES LTDRIVASTIGMINE HYDROGEN TARTRATE

DMF 172492004

DR REDDYS LABORATORIES LTDRIVASTIGMINE HYDROGEN TARTRATE (PROCESS II )

DMF 217812008

INTERQUIM SARIVASTIGMINE

DMF 229742009

AARTI DRUGS LTDRIVASTIGMINE HYDROGEN TARTRATE

DMF 229972009

ACTAVIS GROUP PTC EHFRIVASTIGMINE HYDROGEN TARTRATE (NON-STERILE BULK DRUG SUBSTANCE)

DMF 232652009

JUBILANT BIOSYS LTDRIVASTIGMINE USP

DMF 245022011

ERREGIERRE SPARIVASTIGMINE

DMF 258712011

MATRIX PHARMACORP PRIVATE LTDRIVASTIGMINE USP (PROCESS II)

DMF 264992012

ZYDUS LIFESCIENCES LTDRIVASTIGMINE USP

DMF 275162013

APOTEX PHARMACHEM INCRIVASTIGMINE USP

DMF 290332015

MSN ORGANICS PRIVATE LTDRIVASTIGMINE USP [ROUTE CODE "RP"]

DMF 291332015

ALEMBIC PHARMACEUTICALS LTDRIVASTIGMINE USP

DMF 291992015

APITORIA PHARMA PRIVATE LTDRIVASTIGMINE USP

DMF 295192015

CAMBREX KARLSKOGA ABRIVASTIGMINE

DMF 298262015

MSN ORGANICS PRIVATE LTDRIVASTIGMINE USP

DMF 365292022

SHODHANA LABORATORIES PRIVATE LTDRIVASTIGMINE

DMF 406012024

MYLAN LABORATORIES LTDInactiveRIVASTIGMINE

DMF 244852010

DR REDDYS LABORATORIES LTDInactiveRIVASTIGMINE

DMF 259102012

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — 4.6MG/24HR

0 patents0 exclusivities▴

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Nov 26, 2019

No patent or exclusivity listings for this strength.

#002 — 9.5MG/24HR

0 patents0 exclusivities▾

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Nov 26, 2019

#003 — 13.3MG/24HR

0 patents0 exclusivities▾

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Nov 26, 2019